Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel liposomal - Syncore Biotechnology

Drug Profile

Paclitaxel liposomal - Syncore Biotechnology

Alternative Names: EndoTAG-1; MBT-0206; SB 05

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase III Triple negative breast cancer
  • Phase II Pancreatic cancer
  • No development reported Colorectal cancer; Gastrointestinal cancer; HER2 negative breast cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 04 Jan 2024 No development reported - Phase-III for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, USA, Russia, South Korea, Israel, Hungary, France (IV) (Syncore Biotechnology Pipeline January 2024)
  • 08 Dec 2022 SynCore Biotechnology terminates Phase-III trial in Triple negative Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) due to study design reconsideration (NCT03002103)
  • 19 Feb 2021 Phase III development in Pancreatic cancer (Combination therapy, Second-line therapy or greater) is still ongoing in France, Hungary and Taiwan (IV) (SynCore Biotechnology's pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top